ProCE Banner Activity

BRAF/MEK Inhibitors and High-Dose IL-2 in Melanoma: Adverse Event Management

Slideset Download
This downloadable slideset from an ondemand webcast offers insight into best practices for the management of adverse events associated with different classes of agents used for advanced melanoma including targeted therapy, immunotherapy, and high-dose IL2 therapy.

Released: April 02, 2021

Expiration: April 01, 2022

No longer available for credit.

Share

Faculty

George Ebanks

George Ebanks, RN, BSN, OCN

Cutaneous Medical Oncology Nurse
Cutaneous Oncology Program
Moffitt Cancer Center
Tampa, Florida

Jennifer Swank

Jennifer Swank, PharmD, BCOP

Clinical Pharmacy Specialist, Medical Oncology
Moffitt Cancer Center
Tampa, Florida

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Clinigen Inc

Faculty Disclosure

Primary Author

George Ebanks, RN, BSN, OCN

Cutaneous Medical Oncology Nurse
Cutaneous Oncology Program
Moffitt Cancer Center
Tampa, Florida

Jennifer Swank, PharmD, BCOP

Clinical Pharmacy Specialist, Medical Oncology
Moffitt Cancer Center
Tampa, Florida